Novanta completes acquisition of Riverpoint Medical
NOVT•Novanta closes Riverpoint Medical acquisition
Novanta completed its acquisition of Riverpoint Medical from Arlington Capital Partners.
Riverpoint makes minimally invasive surgical consumables; the deal is expected to lift recurring medical consumables revenue to about $300 million.
Medical end-market exposure is expected to rise to about 60% of total revenue.
The purchase is expected to add $0.18-$0.25 to adjusted EPS in 2027, the first full year post-close.
Riverpoint will be reported in Novanta’s Medical Solutions operating segment.
